RebrAIn provides a SaaS platform that combines advanced AI algorithms with MRI sequences to deliver optimal electrode targeting for deep brain stimulation (DBS) surgeries. The solution is CE-marked and has received FDA authorization. Its product is designed to support neurosurgeons in planning and executing precision neurosurgical interventions. The company intends to use newly raised funds to consolidate its team. RebrAIn also plans to expand international commercialization of its AI-driven neurosurgery solutions. The recent financing strengthens its position to scale clinical adoption and market presence.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2024